As the world’s population ages at an unprecedented rate, the field of longevity research is surging to the forefront of science and investment, highlighted by the rapid growth of events like the Aging Research and Drug Discovery (ARDD) conference. Major pharmaceutical companies and record-breaking funding are accelerating breakthroughs in aging biology, with cutting-edge AI technologies playing a central role. Insilico Medicine stands out as a global leader in AI driven drug discovery and aging research, leveraging advanced AI to discover aging biomarkers, therapeutic targets, and novel interventions—achievements showcased at ARDD 2025 alongside top scientists and innovators. Through ongoing collaboration and innovation, Insilico and its partners are paving the way toward the ultimate goal: achieving healthy longevity for everyone on the planet.
